ASKA Pharmaceutical Holdings Co., Ltd. (JP:4886)
:4886
Want to see JP:4886 full AI Analyst Report?
Top Page
ASKA Pharmaceutical Holdings Co., Ltd.
(4886)
Select Model
Select Model
Rating:78Outperform
Price Target:
Â¥2,648.00
â–²(29.93% Upside)
Action:Reiterated
Date:05/12/26
The score is driven primarily by strong financial positioning (notably major debt reduction and expanding equity) and steady revenue growth, tempered by historically volatile cash flow. Technicals add support via a clear uptrend and positive momentum, while valuation is favorable due to a low P/E and a moderate dividend yield.
Positive Factors
Strengthened balance sheet
Meaningful debt reduction alongside substantial equity growth materially lowers financial risk and increases strategic optionality. This durable improvement supports funding for R&D, capacity investments or M&A without excessive leverage, and strengthens the firm's ability to withstand reimbursement or market shocks over the medium term.
Negative Factors
Volatile cash generation
Large swings in operating cash flow and a negative free cash flow year reduce predictability of internal funding for R&D, capex and shareholder returns. Even with a rebound, such variability suggests working-capital or investment timing risk that can constrain strategic flexibility and stress liquidity in adverse periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened balance sheet
Meaningful debt reduction alongside substantial equity growth materially lowers financial risk and increases strategic optionality. This durable improvement supports funding for R&D, capacity investments or M&A without excessive leverage, and strengthens the firm's ability to withstand reimbursement or market shocks over the medium term.
Read all positive factors
ASKA Pharmaceutical Holdings Co., Ltd. (4886) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
Â¥61.05B
Dividend Yield2.52%
Average Volume (3M)49.10K
Price to Earnings (P/E)12.2
Beta (1Y)0.52
Revenue Growth10.90%
EPS Growth6.19%
CountryJP
Employees762
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)178.85
Shares Outstanding28,763,199
10 Day Avg. Volume37,820
30 Day Avg. Volume49,100
Financial Highlights & Ratios
PEG Ratio1.99
Price to Book (P/B)0.96
Price to Sales (P/S)0.94
P/FCF Ratio17.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)197.8
Revenue Forecast (FY)Â¥71.06B
ASKA Pharmaceutical Holdings Co., Ltd. Business Overview & Revenue Model
Company Description
ASKA Pharmaceutical Holdings Co.,Ltd. is a Japanese enterprise that operates through its subsidiaries in three primary areas: pharmaceuticals, animal healthcare, and hormone testing services. The company's pharmaceutical division is dedicated to t...
How the Company Makes Money
ASKA Pharmaceutical Holdings Co., Ltd. primarily makes money through its consolidated pharmaceutical operations. The core revenue stream is sales of prescription pharmaceuticals marketed by its operating subsidiaries to medical institutions and ph...
ASKA Pharmaceutical Holdings Co., Ltd. Financial Statement Overview
Summary
Income Statement
76
Positive
Balance Sheet
85
Very Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.43B | 71.13B | 64.14B | 62.84B | 60.46B | 56.61B |
| Gross Profit | 31.79B | 34.15B | 31.34B | 30.66B | 28.59B | 26.35B |
| EBITDA | 7.39B | 8.92B | 7.58B | 9.16B | 8.24B | 7.68B |
| Net Income | 5.07B | 5.42B | 5.10B | 7.54B | 4.24B | 4.29B |
Balance Sheet | ||||||
| Total Assets | 102.95B | 112.01B | 103.25B | 93.31B | 87.14B | 83.30B |
| Cash, Cash Equivalents and Short-Term Investments | 7.23B | 11.02B | 11.16B | 17.24B | 17.91B | 17.10B |
| Total Debt | 13.77B | 3.27B | 10.90B | 9.48B | 12.62B | 14.05B |
| Total Liabilities | 33.72B | 35.56B | 34.06B | 31.38B | 32.60B | 34.40B |
| Stockholders Equity | 65.44B | 69.99B | 65.31B | 61.93B | 54.53B | 48.89B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 3.75B | -475.00M | 166.00M | 2.89B | 2.26B |
| Operating Cash Flow | 0.00 | 6.30B | 2.48B | 1.49B | 3.35B | 2.84B |
| Investing Cash Flow | 0.00 | -5.75B | -6.12B | 1.71B | -1.13B | 6.74B |
| Financing Cash Flow | 0.00 | -818.00M | -2.96B | -3.94B | -1.82B | -3.00B |
ASKA Pharmaceutical Holdings Co., Ltd. Technical Analysis
Negative
2038.00
Price Trends
2741.26
Negative
2537.76
Negative
2336.99
Negative
Market Momentum
-129.16
Positive
29.21
Positive
5.95
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4886, the sentiment is Negative. The current price of 2038 is below the 20-day moving average (MA) of 2598.10, below the 50-day MA of 2741.26, and below the 200-day MA of 2336.99, indicating a bearish trend. The MACD of -129.16 indicates Positive momentum. The RSI at 29.21 is Positive, neither overbought nor oversold. The STOCH value of 5.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4886.
ASKA Pharmaceutical Holdings Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥61.05B | 12.16 | ― | 2.52% | 10.90% | 6.19% | |
68 Neutral | ¥59.84B | 24.15 | 5.01% | 2.39% | 17.31% | -24.31% | |
66 Neutral | ¥107.19B | 14.17 | 4.81% | 2.34% | 11.21% | 39.02% | |
63 Neutral | ¥34.24B | 12.06 | ― | 2.75% | 3.94% | 40.63% | |
54 Neutral | ¥57.69B | 18.43 | ― | 3.36% | -2.94% | -62.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥136.33B | 66.79 | -2.58% | 4.16% | -18.25% | -84.71% |
* Healthcare Sector Average
JP:4886
ASKA Pharmaceutical Holdings Co., Ltd.
2,294.00
-120.94
-5.01%
JP:4521
Kaken Pharmaceutical Co
3,785.00
145.07
3.99%
JP:4554
Fuji Pharma Co., Ltd.
2,295.00
1,008.20
78.35%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,150.00
282.01
9.83%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,096.00
-345.01
-23.94%
JP:4577
Daito Pharmaceutical Co., Ltd.
1,187.00
223.35
23.18%
ASKA Pharmaceutical Holdings Co., Ltd. Corporate Events
ASKA Pharma revamps restricted share pay as it shifts to new governance structure
May 25, 2026
ASKA Pharmaceutical Holdings has resolved to revise its restricted share remuneration system for internal board members and introduce a similar scheme for outside directors, aligning compensation more closely with shareholder interests and long-te...
ASKA Pharmaceutical switches auditors to EY ShinNihon to support global expansion
May 25, 2026
ASKA Pharmaceutical Holdings will change its accounting auditor from Seiyo Audit Corporation to Ernst Young ShinNihon LLC, pending approval at its June 24, 2026 shareholders meeting. The move comes after Seiyo’s long tenure since 2011 and r...
ASKA Seeks Shareholder Mandate for Defense Against Potential Dalton-Led Takeover Move
May 25, 2026
ASKA Pharmaceutical Holdings’ board has decided to seek shareholder approval at its June 24, 2026 annual general meeting to implement defensive countermeasures if a consortium led by Dalton Investments proceeds with a large-scale, non-compli...
ASKA Pharma to Embed Corporate Philosophy and Shift to Audit Committee Governance
May 25, 2026
ASKA Pharmaceutical Holdings will seek shareholder approval on June 24, 2026, to amend its Articles of Incorporation by formally embedding its longstanding corporate philosophy of contributing to health and society through innovative products, sig...
ASKA Pharma Corrects Pension Accounting Data Without Affecting FY2026 Earnings
May 19, 2026
ASKA Pharmaceutical Holdings has corrected certain items in its consolidated financial results for the fiscal year ended March 31, 2026, after identifying deficiencies in underlying data used for retirement benefit accounting. The revisions, trigg...
ASKA Pharmaceutical Overhauls Board, Taps Industry Veteran for Governance Role
May 11, 2026
ASKA Pharmaceutical Holdings announced a slate of board and corporate officer changes set to take effect following its June 24, 2026 shareholders meeting, underscoring a governance reshuffle as the company navigates its next phase of growth. The c...
ASKA Pharmaceutical Delivers Record FY2025 Results on Overseas Expansion and Margin Gains
May 11, 2026
ASKA Pharmaceutical Holdings reported consolidated net sales of ¥71.1 billion for FY2025, a 10.9% year-on-year increase, driven by steady growth in its domestic business and contributions from overseas subsidiaries, leading to a record-high o...
ASKA Pharmaceutical Boosts Dividend as Profits Rise but Signals Margin Pressure Ahead
May 11, 2026
ASKA Pharmaceutical Holdings reported consolidated net sales of ¥71.1 billion for the fiscal year ended March 31, 2026, up 10.9% year-on-year, with operating profit rising 9.4% to ¥5.8 billion and profit attributable to owners of the par...
ASKA Pharmaceutical Lifts Dividend and Adopts Progressive Payout Policy
May 11, 2026
ASKA Pharmaceutical Holdings plans to raise its year-end dividend for the fiscal year ended March 31, 2026, to 33 yen per share, bringing the total annual dividend to 60 yen when combined with the 27 yen interim payout. This represents a 5 yen inc...
ASKA Pharmaceutical Board Rejects Activist Shareholder’s Director Proposal
May 11, 2026
ASKA Pharmaceutical Holdings has disclosed that it will oppose a shareholder proposal submitted by Nippon Active Value Fund PLC ahead of its June 24 annual general meeting, which calls for the appointment of two directors who are not audit and sup...
ASKA sets 2035 long-term vision and unveils 2028 medium-term growth plan
Mar 23, 2026
ASKA Pharmaceutical Holdings has unveiled a long-term management blueprint dubbed ASKA VISION 2035, setting a 10-year ambition to achieve sustainable growth while enhancing its contribution to society through purpose-driven business execution. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.